Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H17ClF6N2O2
CAS Number:
Molecular Weight:
478.82
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
O=C(N1CCCC(C(NC2=CC=C(Cl)C=C2)=O)C1)C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3
InChI
1S/C21H17ClF6N2O2/c22-16-3-5-17(6-4-16)29-18(31)12-2-1-7-30(11-12)19(32)13-8-14(20(23,24)25)10-15(9-13)21(26,27)28/h3-6,8-10,12H,1-2,7,11H2,(H,29,31)
InChI key
MOQCFMZWVKQBAP-UHFFFAOYSA-N
Biochem/physiol Actions
CCG-100602 aids in preventing fibrosis around the temporomandibular joint (TMJ).
CCG-100602 is a CCG-1423 analog with significantly less cytotoxicity (0/14% WST-1 inhibition by 10/100 μM CCG-100602 vs. 44% by 10 μM CCG-1423) and similar efficacy against Rho/MKL1/SRF pathway-mediated transcription (by 78% with 100 μM CCG-100602 vs. 74% with 10 μM CCG-1423; IC50 = 9.8 μM/CCG-100602 vs. 1.5 μM/CCG-1423; by PC-3 SRE-luciferase assay), albeit at a reduced potency. CCG-100602 reduces the stiffening of spontaneously hypertensive rats (SHR) derived aortic VSMCs (1.12 μM) by inhibiting SRF/myocardin interaction and abrogates the increased aortic wall stiffness in SHR rats in vivo (7.5 mg/kg/d via s.c. osmotic pumps for 2 wks).
CCG-1423 analog with similar efficacy and much less cytotoxicity. Inhibits SRF/myocardin interaction and reduces aortic VSMCs stiffening in vitro and in vivo.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mark B Lucera et al.
Retrovirology, 14(1), 4-4 (2017-01-25)
HIV-1 hijacks host cell machinery to ensure successful replication, including cytoskeletal components for intracellular trafficking, nucleoproteins for pre-integration complex import, and the ESCRT pathway for assembly and budding. It is widely appreciated that cellular post-translational modifications (PTMs) regulate protein activity
Konstantin Tsoyi et al.
American journal of respiratory cell and molecular biology, 58(2), 208-215 (2017-09-09)
Radiation-induced pulmonary fibrosis is a severe complication of patients treated with thoracic irradiation. We have previously shown that syndecan-2 reduces fibrosis by exerting alveolar epithelial cytoprotective effects. Here, we investigate whether syndecan-2 attenuates radiation-induced pulmonary fibrosis by inhibiting fibroblast activation.
Chris R Evelyn et al.
Bioorganic & medicinal chemistry letters, 20(2), 665-672 (2009-12-08)
We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2292-5MG | 04061835350155 |
| SML2292-25MG | 04061835350148 |